£2.1M
Origin Capital co-led the £2.1m funding round for the nanoparticle technology developer.
S
Somaserve
Somaserve builds specialised nanoparticle technologies for targeted drug delivery.
United Kingdom
£2.1MTotal raised
Somaserve develops specialised nanoparticle technologies designed to transport pharmaceutical and therapeutic agents to specific cell types.
Categories
Investors
